Gadobutrol - CAS 770691-21-9
Catalog number: B0084-463325
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C18H31GdN4O9
Molecular Weight:
604.71
COA:
Certificate of Analysis-Gadobutrol 770691-21-9 B15H1014  
Targets:
Others
Description:
Gadobutrol is a nonionic, paramagnetic contrast agent developed for tissue contrast enhancement in magnetic resonance imaging (MRI). It has a macrocyclic framework and is neutral. It is a water-soluble, highly hydrophilic compound with a partition coefficient between n-butanol and buffer at pH 7.6 of ~ 0.006.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-463325 1 g $298 In stock
Bulk Inquiry
Publictions citing BOC Sciences Products
  • >> More
Purity:
≥ 99.5%
Related CAS:
138071-82-6
Appearance:
White, odorless amorphous powder
Synonyms:
Gadograf; Gadovist; Protovist; ZK 135079; Gd-DO3A-butrol; Gallium 10-(1,3,4-trihydroxybutan-2-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-tricarboxylate; 770691-21-9; AK325914; gallium; 10-(1,3,4-trihydroxybutan-2-yl)-1,4,7,10-tetrazacyclododecane-1,4,7-tricarboxylate; (SA-​8-​1425362’5’)​-[rel-​10-​[(2R,​3S)​-​2-​(hydroxy-​κO)​-​3-​hydroxy-​1-​(hydroxymethyl)​propyl]​-​1,​4,​7,​10-​tetraazacyclododecan​e-​1,​4,​7-​triacetato(3-​)​-​κN1,​κN4,​κN7,​κN10,​κO1,​κO4,​κO7]​-​gadolinium;
Solubility:
Easily soluble in water, slightly soluble in methanol and ethanol, practically insoluble in chloro-form and acetone.
MSDS:
Inquire
Application:
A gadolinium-based MRI contrast agent (GBCA)
Quality Standard:
In-house standard
Quantity:
Grams-Kilos
Melting Point:
>300ºC (dec.)
InChIKey:
NMVNSVAWXBUTGC-UHFFFAOYSA-K
InChI:
1S/C15H28N4O9.Ga/c20-9-11(12(22)10-21)16-1-3-17(13(23)24)5-7-19(15(27)28)8-6-18(4-2-16)14(25)26;/h11-12,20-22H,1-10H2,(H,23,24)(H,25,26)(H,27,28);/q;+3/p-3
Canonical SMILES:
C1CN(CCN(CCN(CCN1C(CO)C(CO)O)C(=O)[O-])C(=O)[O-])C(=O)[O-].[Ga+3]
1.Gadobutrol: an alternative contrast agent for digital subtraction dacryocystography
M. Priebe, A. Mohr, J. Brossmann, M. Heller, C. Frahm. Eur Radiol (2002) 12:2083–2086
Theoretically, X-ray attenuation of gadolinium compares favorably with that of iodine, as the absorption of Xrays depends on the atomic number to the third power. With an atomic number of 64 and a k-edge of 52 keV, gadolinium has photoelectric characteristics similar to those of iodine (atomic number of 53 and k-edge of 33.2 keV); thus, a higher X-ray absorption can be expected from gadolinium. Gadobutrol has the double gadolinium concentration (1.0 mmol/l or 157.34 mg/ml) of the other gadolinium-based contrast agents, resulting in a high radiodensity which is very similar to that of iodinated contrast medium iopentol with a iodine concentration of 250 mg/ml. Due to the high concentration, the radiodensity of gadobutrol is only approximately 20% lower than the concentration of iopentol (300 mg iodine/ml). This correlates well with our impression that the image contrast of DS-DCG with gadobutrol was only slightly inferior to routine DS-DCG studies performed with iopentol.
2.Safety of contrast-enhanced MR angiography employing gadobutrol 1.0 M as contrast material
Jörn O. Balzer, Christian Loewe, Kirsten Davis. Eur Radiol (2003) 13:2067–2074
In three multicenter studies (body MRA study, peripheral MRA study, safety study) conducted in 27 centers from January to December 2000 a total of 436 patients were recruited for CE MRA employing intravenous injections of the new contrast agent 1.0-M gadobutrol (Gadovist, Schering, Berlin, Germany; Table 1). One patient did not receive the study drug and was excluded; thus, the data of 435 patients was included in order to evaluate the clinical safety of 1.0-M gadobutrol injections. Due to organizational limits, not all participating centers had the opportunity to collect data on all safety parameters during the follow-up period. Adverse events (i.e., all adverse reactions observed by the investigator or reported by the patient during the follow-up period) were evaluated in all patients, laboratory values were available from 124 patients, and vital signs (blood pressure and heart rate after at least 5 min recumbence) as well as 12-lead electrocardiogram (ECG) recordings from 93 patients.
3.Double-dose 1.0-M gadobutrol versus standard-dose 0.5-M gadopentetate dimeglumine in revealing small hypervascular hepatocellular carcinomas
Young Kon Kim, Young Hwan Lee, Chong Soo Kim. Eur Radiol (2008) 18: 70–77
Our study result from matched pairs analysis, in which superior lesion-to-liver contrast was noted by all observers for one lesion with gadopentetate dimeglumine compared with gadobutrol despite the low gadolinium concentration of the gadopentetate dimeglumine, is totally opposite to the theoretical expectation. This is because all the study conditions of the two MRIs, except for the contrast agent and the physiologic aspects were all kept constant to permit a direct comparison. In this study, even though the modified VIBE sequence with mSENSE for inducing increased temporal resolution and the resultant double arterial phases were used, as well as a test-bolus technique, two small HCCs were not clearly demonstrated with either MRI. This could be interpreted to mean that it is still difficult to accurately capture the very short enhancement period of small HCCs with MR technology in our study. In other words, under the circumstance of using the 3D-dynamic MR sequence, the accurate timing to capture the arterial phase imaging might be given much more weight for detecting HCCs than the concerns about what extracellular MR contrast agent is used. However, the potential of a more highly concentrated gadolinium chelate has to be further investigated by additional studies using ultra-fast MR equipment, where a compact bolus is advantageous, or an MR protocol such as 2D-dynamic imaging with longer data acquisition time (≈20 s).
4.Intraindividual, randomized comparison of the macrocyclic contrast agents gadobutrol and gadoterate meglumine in breast magnetic resonance imaging
Eva M. Fallenberg & Diane M. Renz & Bettina Karle & Carsten Schwenke. Eur Radiol (2015) 25:837–849
The aim of our study was to investigate whether gadobutrol and gadoterate meglumine differ not only with regard to peak enhancement, which is expected on the basis of their different T1-relaxivities, but also with regard to the time course of signal enhancement, which might be attributable to differences in electric charge. We, therefore, performed an intraindividual comparison of the signal intensity time courses after gadobutrol and gadoterate meglumine administration in women with different benign and malignant breast lesions.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products


CAS 121268-17-5 Alendronate sodium hydrate

Alendronate sodium hydrate
(CAS: 121268-17-5)

Alendronate, a nitrogen-containing bisphosphonate, is a potent inhibitor of bone resorption used for the treatment and prevention of osteoporosis.

CAS 76901-59-2 Speract

Speract
(CAS: 76901-59-2)

Speract, a peptide associated with eggs of sea urchin, Lytechinus pictus, regulates sperm motility, also stimulates sperm mitochondrial metabolism.

Trodusquemine
(CAS: 186139-09-3)

Trodusquemine, also called as MSI-1436 or Aminosterol-1436, with the potential to treat type 2 diabetes and obesity, it is a non-competitive cholestane inihbito...

CAS 547-44-4 Sulfacarbamide

Sulfacarbamide
(CAS: 547-44-4)

Sulfacarbamide is an antibiotic acting on the vegetative nervous system.

CHEMBL2426474
(CAS: 1418741-86-2)

CHEMBL2426474, also called as UNC1079, the piperidine analog of UNC1021 that has binding affinity to L3MBTL3 in human G401 cells by Western blot based pulldown ...

CAS 19309-14-9 Cardamonin

Cardamonin
(CAS: 19309-14-9)

Cardamonin is a naturally occuring chalcone initially isolated from the seeds of Amomum subulatum and subsequently from other zingiberous plant species. Cardamo...

CAS 1256094-72-0 AI-10-49

AI-10-49
(CAS: 1256094-72-0)

AI-10-49 is a protein-protein interaction inhibitor that selectively binds to CBFβ-SMMHC and disrupts its binding to RUNX1 with a FRET IC50 of 0.26 uM.

CAS 57852-42-3 Resiniferonol 9,13,14-Orthophenylacetate

Resiniferonol 9,13,14-Orthophenylacetate
(CAS: 57852-42-3)

Resiniferonol 9,13,14-Orthophenylacetate, a 20-Deacylated derivative of resiniferatoxin and tinyatoxin, is a transient receptor potential vanilloid-1 (TRPV1) ag...

GSK894490A
(CAS: 1012035-06-1)

GSK894490A is a non-peptide ghrelin receptor agonist. It crosses the blood/brain barrier and elicit pro-cognitive effects in recognition and spatial learning an...

CAS 2809-21-4 Etidronic acid

Etidronic acid
(CAS: 2809-21-4)

Etidronate (Didronel) is a human protein tyrosine phosphatase inhibitor with IC50 of 0.2 μM.

CAS 176975-26-1 Izonsteride

Izonsteride
(CAS: 176975-26-1)

Izonsteride, a benzothiazolyl derivative, has been found to be a cholestenone 5-alpha reductase inhibitor that was once studied in prostate cancer and probably ...

CAS 474-86-2 Equilin

Equilin
(CAS: 474-86-2)

Equilin is one of the estrogens present in the mixture of estrogens isolated from horse urine and marketed as Premarin.

LY-113174
(CAS: 112959-07-6)

LY-113174 is a novel class of nonsteroidal aromatase inhibitor. It may prove useful in the treatment of estrogen-dependent diseases.

CP-664511
(CAS: 379692-00-9)

CP-664511 is a potent compound that is a alpha4beta1/vascular cell adhesion molecule-1 (VCAM-1) inhibitor which has therapeutic potential in treating allergic a...

CAS 2901-75-9 N-Acetyl-DL-phenylalanine

N-Acetyl-DL-phenylalanine
(CAS: 2901-75-9)

N-Acetyl-DL-phenylalanine is a drug to treat depression.

CAS 47141-42-4 Levobunolol

Levobunolol
(CAS: 47141-42-4)

Levobunolol is a nonselective beta-adrenoceptor antagonist used in the treatment of glaucoma.

CAS 630-56-8 17α-Hydroxyprogesterone Caproate

17α-Hydroxyprogesterone Caproate
(CAS: 630-56-8)

17α-Hydroxyprogesterone Caproate , a synthetic steroidal progestin, is an ester derivative of 17α-hydroxyprogesterone formed from caproic acid used in the treat...

CAS 434-05-9 Methenolone acetate

Methenolone acetate
(CAS: 434-05-9)

Metenolone enanthate,is a dihydrotestosterone based anabolic steroid with weak androgenic properties.

CAS 75-80-9 Tribromoethanol

Tribromoethanol
(CAS: 75-80-9)

Tribromoethanol is a sedative. It is used to anesthetize laboratory animals, particularly rodents, prior to surgery. It has the brand name Avertin as a solution...

CAS 4547-24-4 Corosolic acid

Corosolic acid
(CAS: 4547-24-4)

Corosolic acid, that is isolated from the barks of Lagerstroemia speciosa, contains anti-angiogenic activity that can suppress FAK signaling induced by angiopoi...

Chemical Structure

CAS 770691-21-9 Gadobutrol

Quick Inquiry

Verification code

Featured Items